NCT00987935 - A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2014

Study Completion Date

January 31, 2016

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Sorafenib

400 mg twice daily

DRUG

BIBF 1120

Twice daily

Trial Locations (16)

1199.39.82001 Boehringer Ingelheim Investigational Site, Seoul

1199.39.82002 Boehringer Ingelheim Investigational Site, Seoul

1199.39.82003 Boehringer Ingelheim Investigational Site, Seoul

1199.39.82004 Boehringer Ingelheim Investigational Site, Seoul

1199.39.82005 Boehringer Ingelheim Investigational Site, Seoul

1199.39.82006 Boehringer Ingelheim Investigational Site, Seoul

1199.39.88606 Boehringer Ingelheim Investigational Site, Changhua

1199.39.88609 Boehringer Ingelheim Investigational Site, Kaohsiung City

1199.39.88610 Boehringer Ingelheim Investigational Site, Kaohsiung City

1199.39.88605 Boehringer Ingelheim Investigational Site, Taichung

1199.39.88602 Boehringer Ingelheim Investigational Site, Tainan City

1199.39.88608 Boehringer Ingelheim Investigational Site, Tainan City

1199.39.88601 Boehringer Ingelheim Investigational Site, Taipei

1199.39.88603 Boehringer Ingelheim Investigational Site, Taipei

1199.39.88604 Boehringer Ingelheim Investigational Site, Taoyuan

1199.39.88607 Boehringer Ingelheim Investigational Site, Yunlin County